Oncolytics Biotech Inc
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal aden… Read more
Oncolytics Biotech Inc (ONCY) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -57.835x
Based on the latest financial reports, Oncolytics Biotech Inc (ONCY) has a cash flow conversion efficiency ratio of -57.835x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.65 Million) by net assets ($115.00K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Oncolytics Biotech Inc - Cash Flow Conversion Efficiency Trend (1999–2024)
This chart illustrates how Oncolytics Biotech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Oncolytics Biotech Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Oncolytics Biotech Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Enwei Pharmaceutical Co. Ltd. A
SHE:301331
|
N/A |
|
Globus Spirits Limited
NSE:GLOBUSSPR
|
0.260x |
|
ECARX Holdings Inc. Class A Ordinary shares
NASDAQ:ECX
|
-0.018x |
|
FutureFuel Corp
NYSE:FF
|
-0.007x |
|
Bonduelle SCA
F:BDU
|
0.228x |
|
Smartoptics Group AS
OL:SMOP
|
0.323x |
|
Shenzhen Properties & Resources Development Group Ltd
SHE:200011
|
-0.111x |
|
Mersana Therapeutics Inc
NASDAQ:MRSN
|
0.054x |
Annual Cash Flow Conversion Efficiency for Oncolytics Biotech Inc (1999–2024)
The table below shows the annual cash flow conversion efficiency of Oncolytics Biotech Inc from 1999 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $5.98 Million | $-26.97 Million | -4.507x | -336.69% |
| 2023-12-31 | $27.56 Million | $-28.45 Million | -1.032x | -17.12% |
| 2022-12-31 | $26.50 Million | $-23.36 Million | -0.881x | -41.80% |
| 2021-12-31 | $36.10 Million | $-22.43 Million | -0.621x | +30.29% |
| 2020-12-31 | $24.75 Million | $-22.07 Million | -0.892x | -100.48% |
| 2019-12-31 | $-107.89K | $-19.91 Million | 184.497x | +9688.95% |
| 2018-12-31 | $6.20 Million | $-11.92 Million | -1.924x | -7.03% |
| 2017-12-31 | $8.28 Million | $-14.89 Million | -1.798x | -54.00% |
| 2016-12-31 | $10.69 Million | $-12.48 Million | -1.167x | -91.56% |
| 2015-12-31 | $24.67 Million | $-15.03 Million | -0.609x | +57.21% |
| 2014-12-31 | $13.82 Million | $-19.68 Million | -1.424x | -29.41% |
| 2013-12-31 | $22.21 Million | $-24.44 Million | -1.100x | +52.51% |
| 2012-12-31 | $14.79 Million | $-34.26 Million | -2.317x | -203.39% |
| 2011-12-31 | $29.52 Million | $-22.54 Million | -0.764x | -77.55% |
| 2010-12-31 | $41.93 Million | $-18.03 Million | -0.430x | +16.02% |
| 2009-12-31 | $32.84 Million | $-16.82 Million | -0.512x | +68.33% |
| 2008-12-31 | $9.45 Million | $-15.29 Million | -1.617x | -233.25% |
| 2007-12-31 | $27.96 Million | $-13.57 Million | -0.485x | -22.97% |
| 2006-12-31 | $30.80 Million | $-12.16 Million | -0.395x | -58.73% |
| 2005-12-31 | $44.45 Million | $-11.05 Million | -0.249x | -3.47% |
| 2004-12-31 | $38.39 Million | $-9.22 Million | -0.240x | -9.74% |
| 2003-12-31 | $25.02 Million | $-5.48 Million | -0.219x | +50.03% |
| 2002-12-31 | $16.56 Million | $-7.26 Million | -0.438x | -63.61% |
| 2001-12-31 | $15.95 Million | $-4.27 Million | -0.268x | -68.90% |
| 2000-12-31 | $19.92 Million | $-3.16 Million | -0.159x | -105.58% |
| 1999-12-31 | $6.93 Million | $-534.35K | -0.077x | -- |